CNS Drugs

, Volume 25, Issue 10, pp 819–827

Maintenance Treatment Study Designs in Bipolar Disorder

Do They Demonstrate that Atypical Neuroleptics (Antipsychotics) are Mood Stabilizers?
  • Frederick K. Goodwin
  • Elizabeth A. Whitham
  • S. Nassir Ghaemi
Current Opinion


In this conceptual review we argue that by certifying some of the atypical neuroleptics (or, if one prefers, antipsychotics) as indicated for the ‘maintenance’ treatment of bipolar disorder, the US FDA has created confusion in the field. These maintenance indications are based on studies using a ‘relapse prevention’ design, a design that does not address whether the agents tested can prevent new episodes of illness, i.e. recurrence prevention or true prophylaxis.

We found that the relapse prevention design fails to prove that these agents are mood stabilizers because patients are pre-selected to respond to the study drug for an acute mood episode (mania) and when they relapse, they do so into an episode of the same polarity (i.e. mania). We believe that this represents withdrawal into the same mood episode that patients experienced before the maintenance study began, rather than prevention of a new mood episode, as research into the natural history of bipolar disorder indicates that such new episodes typically are of the opposite polarity. Thus, the inability of neuroleptics to prevent depression in such maintenance studies reflects the general inability to prevent any new mood episode recurrence (which we believe should be defined as 6 months or longer after the index episode).

If one defines a mood stabilizer, as we do, as a drug that prevents new episodes of mania and depression in monotherapy, then these studies do not show that atypical neuroleptics are mood stabilizers. Future maintenance research studies in bipolar disorder should use the prophylaxis design (i.e. without pre-selection of drug responders), rather than the relapse prevention design.


  1. 1.
    Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004 Mar; 65(3): 432–41PubMedCrossRefGoogle Scholar
  2. 2.
    Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006 Feb; 163(2): 247–56PubMedCrossRefGoogle Scholar
  3. 3.
    Keck Jr PE, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007 Oct; 68(10): 1480–91PubMedCrossRefGoogle Scholar
  4. 4.
    Bowden C, Swann A, Calabrese J, et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997; 33: 693–9PubMedGoogle Scholar
  5. 5.
    Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. J Clin Psychiatry 1999; 60 Suppl. 5: 5–13, discussion 4-5Google Scholar
  6. 6.
    Goodwin F, Jamison K. Manic depressive illness. 2nd ed. New York (NY): Oxford University Press, 2007Google Scholar
  7. 7.
    Ghaemi SN. On defining ‘mood stabilizer’. Bipolar Disord 2001; 3(3): 154–8PubMedCrossRefGoogle Scholar
  8. 8.
    Ayd FJ, editor. Lexicon of psychiatry, neurology, and the neuroscience. Philadelphia (PA): Lippincott, Williams, and Wilkins, 2000Google Scholar
  9. 9.
    Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of reoccurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082–8PubMedCrossRefGoogle Scholar
  10. 10.
    Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand 2004 Feb; 109(2): 91–5PubMedCrossRefGoogle Scholar
  11. 11.
    Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009 Aug; 11(5): 453–73PubMedCrossRefGoogle Scholar
  12. 12.
    Bowden C, Calabrese J, McElroy S, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481–9PubMedCrossRefGoogle Scholar
  13. 13.
    Bowden C, Calabrese J, Sachs G, et al., Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400PubMedCrossRefGoogle Scholar
  14. 14.
    Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003 Sep; 64(9): 1013–24PubMedCrossRefGoogle Scholar
  15. 15.
    Calabrese JR, Vieta E, El-Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004 Dec 15; 56(12): 957–63PubMedCrossRefGoogle Scholar
  16. 16.
    Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 3rd ed. New York (NY): Springer-Verlag, 1998Google Scholar
  17. 17.
    Calabrese JR, Goldberg JF, Ketter TA, et al. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 2006 Jun 1; 59(11): 1061–4PubMedCrossRefGoogle Scholar
  18. 18.
    Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009 Dec; 11(8): 827–39PubMedCrossRefGoogle Scholar
  19. 19.
    Quiroz J, Lakshmi Y, Palumbo J, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156–62PubMedCrossRefGoogle Scholar
  20. 20.
    Pfizer, Data on file, 2010Google Scholar
  21. 21.
    Weisler R, Nolen W, Neijber A, et al. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. 60th Institute on Psychiatric Services Congress; 2008 Oct 2–5; Chicago (IL)Google Scholar
  22. 22.
    Bang H, Davis CE. On estimating treatment effects under non-compliance in randomized clinical trials: are intent-to-treat or instrumental variables analyses perfect solutions? Stat Med 2007 Feb 28; 26(5): 954–64PubMedCrossRefGoogle Scholar
  23. 23.
    Tanaka Y, Matsuyama Y, Ohashi Y. Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Stat Med 2008 May 10; 27(10): 1718–33PubMedCrossRefGoogle Scholar
  24. 24.
    Peduzzi P, Detre K, Wittes J, et al. Intent-to-treat analysis and the problem of crossovers: an example from the Veterans Administration coronary bypass surgery study. J Thorac Cardiovasc Surg 1991 Mar; 101(3): 481–7PubMedGoogle Scholar
  25. 25.
    Deshauer D, Fergusson D, Duffy A, et al. Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect. Bipolar Disord 2005 Aug; 7(4): 382–7PubMedCrossRefGoogle Scholar
  26. 26.
    Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010 Jan 30; 375(9712): 385–95PubMedCrossRefGoogle Scholar
  27. 27.
    Briscoe B, El-Mallakh R. The evidence base for the long-term use of antidepressants as prophylaxis against future depressive episodes [poster]. American Psychiatric Association Annual Meeting; 2010 May 23–26; New Orleans (LA)Google Scholar
  28. 28.
    Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010; 167(7): 792–800PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Frederick K. Goodwin
    • 1
  • Elizabeth A. Whitham
    • 2
  • S. Nassir Ghaemi
    • 2
    • 3
  1. 1.Center on Neuroscience, Medical Progress, and SocietyThe George Washington University School of MedicineWashington, DCUSA
  2. 2.Mood Disorders ProgramTufts Medical CenterBostonUSA
  3. 3.Department of Psychiatry, Tufts Medical CenterTufts University School of MedicineBostonUSA

Personalised recommendations